Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
160 hedge funds and large institutions have $337M invested in Clovis Oncology, Inc. in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 69 increasing their positions, 30 reducing their positions, and 28 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 165 → 160 (-5)
9% less capital invested
Capital invested by funds: $371M → $337M (-$33.7M)
14% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 28
16% less call options, than puts
Call options by funds: $21.8M | Put options by funds: $26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.4M |
| 2 |
BlackRock
New York
|
+$5.84M |
| 3 |
Morgan Stanley
New York
|
+$3.24M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.64M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.46M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.47M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.18M |
| 4 |
Goldman Sachs
New York
|
-$1.02M |
| 5 |
SC
Sculptor Capital
New York
|
-$925K |
CLVS Hedge Fund Activity: Q2 2021 in Review
160 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2021, worth a combined $337M — down 9.1% from $371M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CLVS and 24 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 69 added.
The largest buyer was Vanguard Group, adding an estimated $13.4M. The largest seller was Candriam SCA, exiting entirely with an estimated $2.46M sold.
- 160 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2021, down from 165 in Q1 2021.
- Funds reported $337M of Clovis Oncology, Inc. stock for Q2 2021, down 9.1% quarter-over-quarter.
- 24 funds opened new Clovis Oncology, Inc. positions in Q2 2021 and 28 closed out, a net change of -4 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2021 was Vanguard Group, an estimated $13.4M added.
- The largest Clovis Oncology, Inc. seller in Q2 2021 was Candriam SCA, an estimated $2.46M sold.
Based on aggregated 13F filings for Q2 2021.